FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151673940> ?p ?o ?g. }

• W2151673940 endingPage "743" @default.
• W2151673940 startingPage "733" @default.
• W2151673940 abstract "Activation of nuclear hormone receptor peroxisome proliferator-activated receptor β/δ (PPARβ) has been shown to improve insulin resistance and plasma high-density lipoprotein levels, but nothing is known about its effects in genetic hypertension. We studied whether the PPARβ agonist GW0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHRs). The rats were divided into 4 groups, Wistar Kyoto rat-control, Wistar Kyoto rat-treated (GW0742, 5 mg · kg(-1) · day(-1) by oral gavage), SHR-control, and SHR-treated, and followed for 5 weeks. GW0742 induced a progressive reduction in systolic arterial blood pressure and heart rate in SHRs and reduced the mesenteric arterial remodeling, the increased aortic vasoconstriction to angiotensin II, and the endothelial dysfunction characteristic of SHRs. These effects were accompanied by a significant increase in endothelial NO synthase activity attributed to upregulated endothelial NO synthase and downregulated caveolin 1 protein expression. Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1β, interleukin 6, or intercellular adhesion molecule 1. None of these effects were observed in Wistar Kyoto rats. PPARβ activation, both in vitro and in vivo, increased the expression of the regulators of G protein-coupled signaling proteins RGS4 and RGS5, which negatively modulated the vascular actions of angiotensin II. PPARβ activation exerted antihypertensive effects, restored the vascular structure and function, and reduced the oxidative, proinflammatory, and proatherogenic status of SHRs. We propose PPARβ as a new therapeutic target in hypertension." @default.
• W2151673940 created "2016-06-24" @default.
• W2151673940 creator A5002326750 @default.
• W2151673940 creator A5009843783 @default.
• W2151673940 creator A5011420908 @default.
• W2151673940 creator A5015114045 @default.
• W2151673940 creator A5017444131 @default.
• W2151673940 creator A5021273363 @default.
• W2151673940 creator A5021507766 @default.
• W2151673940 creator A5023191019 @default.
• W2151673940 creator A5051759673 @default.
• W2151673940 creator A5059648758 @default.
• W2151673940 creator A5077098934 @default.
• W2151673940 creator A5081162021 @default.
• W2151673940 creator A5084623504 @default.
• W2151673940 creator A5090170813 @default.
• W2151673940 creator A5091062427 @default.
• W2151673940 creator A5091585058 @default.
• W2151673940 date "2011-10-01" @default.
• W2151673940 modified "2023-10-18" @default.
• W2151673940 title "Antihypertensive Effects of Peroxisome Proliferator-Activated Receptor-β Activation in Spontaneously Hypertensive Rats" @default.
• W2151673940 cites W1964716328 @default.
• W2151673940 cites W1968096578 @default.
• W2151673940 cites W1972599573 @default.
• W2151673940 cites W1978440962 @default.
• W2151673940 cites W1978737330 @default.
• W2151673940 cites W1981029023 @default.
• W2151673940 cites W1985516506 @default.
• W2151673940 cites W2003269305 @default.
• W2151673940 cites W2008589779 @default.
• W2151673940 cites W2010572876 @default.
• W2151673940 cites W2017671227 @default.
• W2151673940 cites W2017931534 @default.
• W2151673940 cites W2040134719 @default.
• W2151673940 cites W2047191978 @default.
• W2151673940 cites W2053811269 @default.
• W2151673940 cites W2057691476 @default.
• W2151673940 cites W2058562094 @default.
• W2151673940 cites W2059906195 @default.
• W2151673940 cites W2097457805 @default.
• W2151673940 cites W2101318553 @default.
• W2151673940 cites W2103185024 @default.
• W2151673940 cites W2109168147 @default.
• W2151673940 cites W2117561787 @default.
• W2151673940 cites W2123404136 @default.
• W2151673940 cites W2124311386 @default.
• W2151673940 cites W2131374289 @default.
• W2151673940 cites W2133666147 @default.
• W2151673940 cites W2134066661 @default.
• W2151673940 cites W2136741529 @default.
• W2151673940 cites W2139130558 @default.
• W2151673940 cites W2141783395 @default.
• W2151673940 cites W2160761045 @default.
• W2151673940 cites W2165611171 @default.
• W2151673940 cites W2166243320 @default.
• W2151673940 cites W2336903283 @default.
• W2151673940 doi "https://doi.org/10.1161/hypertensionaha.111.174490" @default.
• W2151673940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21825230" @default.
• W2151673940 hasPublicationYear "2011" @default.
• W2151673940 type Work @default.
• W2151673940 sameAs 2151673940 @default.
• W2151673940 citedByCount "78" @default.
• W2151673940 countsByYear W21516739402012 @default.
• W2151673940 countsByYear W21516739402013 @default.
• W2151673940 countsByYear W21516739402014 @default.
• W2151673940 countsByYear W21516739402015 @default.
• W2151673940 countsByYear W21516739402016 @default.
• W2151673940 countsByYear W21516739402017 @default.
• W2151673940 countsByYear W21516739402018 @default.
• W2151673940 countsByYear W21516739402019 @default.
• W2151673940 countsByYear W21516739402020 @default.
• W2151673940 countsByYear W21516739402021 @default.
• W2151673940 countsByYear W21516739402022 @default.
• W2151673940 countsByYear W21516739402023 @default.
• W2151673940 crossrefType "journal-article" @default.
• W2151673940 hasAuthorship W2151673940A5002326750 @default.
• W2151673940 hasAuthorship W2151673940A5009843783 @default.
• W2151673940 hasAuthorship W2151673940A5011420908 @default.
• W2151673940 hasAuthorship W2151673940A5015114045 @default.
• W2151673940 hasAuthorship W2151673940A5017444131 @default.
• W2151673940 hasAuthorship W2151673940A5021273363 @default.
• W2151673940 hasAuthorship W2151673940A5021507766 @default.
• W2151673940 hasAuthorship W2151673940A5023191019 @default.
• W2151673940 hasAuthorship W2151673940A5051759673 @default.
• W2151673940 hasAuthorship W2151673940A5059648758 @default.
• W2151673940 hasAuthorship W2151673940A5077098934 @default.
• W2151673940 hasAuthorship W2151673940A5081162021 @default.
• W2151673940 hasAuthorship W2151673940A5084623504 @default.
• W2151673940 hasAuthorship W2151673940A5090170813 @default.
• W2151673940 hasAuthorship W2151673940A5091062427 @default.
• W2151673940 hasAuthorship W2151673940A5091585058 @default.
• W2151673940 hasBestOaLocation W21516739401 @default.
• W2151673940 hasConcept C126322002 @default.
• W2151673940 hasConcept C134018914 @default.
• W2151673940 hasConcept C164027704 @default.
• W2151673940 hasConcept C170493617 @default.
• W2151673940 hasConcept C185592680 @default.
• W2151673940 hasConcept C2776151105 @default.

• next